Meaxin (Imatinib)

Imatinib works by binding to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. This blocks the enzymes’ activity, preventing downstream phosphorylation events that promote cell proliferation and survival. The inhibition leads to reduced tumor growth and can trigger apoptosis in cells that depend on these kinases.

The appropriate dose of Meaxin is determined by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. Dosage regimens are individualized and should follow the latest clinical guidelines and the prescriber’s clinical judgment.

Safety data for imatinib during pregnancy and lactation are limited. The drug may cross the placenta and be present in breast milk, potentially affecting fetal or infant development. Use is generally avoided unless the potential benefit justifies the risk, and decisions should be made in consultation with a specialist.

To order Meaxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meaxin (imatinib) is the first‑generation BCR‑ABL inhibitor and is often used as a reference standard. Newer agents such as dasatinib or nilotinib may offer higher potency or activity against certain resistant mutations, but they also have distinct safety profiles. Choice of therapy depends on disease characteristics, mutation status and individual patient tolerance.

Meaxin tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, climate‑controlled environment helps maintain its stability and potency throughout its shelf life.

Meaxin is taken orally as a tablet, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any dietary considerations to ensure consistent absorption.

The most serious adverse events linked to imatinib include hepatotoxicity (elevated liver enzymes or hepatitis), severe neutropenia or leukopenia that can predispose to infection, and cardiac complications such as heart failure or reduced left‑ventricular function. Prompt monitoring and medical attention are essential if these events occur.

Meaxin should be avoided in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant or breastfeeding unless the benefits outweigh the risks.